Hugel Aesthetics Breaks Into US Market with Letybo: A New Challenger for Botox

Hugel Aesthetics, a notable player in the cosmetic treatment industry, has finally received approval for its innovative neurotoxin injection, Letybo, targeting moderate to severe frown lines. This breakthrough comes after a challenging journey, including a rejection in March 2022 due to concerns primarily associated with chemistry, manufacturing, controls (CMC), and the need for general updates, according to the company. Despite these hurdles and a subsequent rejection the following year, Letybo has now made its way into the US market, where it is set to rival established brands like Botox.